Novo Nordisk is losing GLP-1 and diabetes market share in key regions as Eli Lilly's Zepbound and Mounjaro gain U.S.

It's part of a struggle other school districts in North Carolina and beyond are having as costs go up and enrollment flattens ...

Washington has launched its study into reparations for slavery and systemic racism. A new survey ask descendants of enslaved ...

Secretary of the Navy John Phelan was fired on Wednesday after months of infighting with senior Pentagon leaders, including ...

Applying an 8x forward P/E multiple, Micron's 12-month fair value is justified at $900 per share under conservative revenue & ...

A new study is intensifying the debate over how generative artificial intelligence (genAI) systems use creative content, warning that current consent mechanisms are fundamentally flawed. The research ...

SaySo, a new short-form video app, aims to restore trust in news by offering curated content from verified creators.

From Jen Liu’s pounds of flesh to Josh Kline’s viral essay, the feeling that something is irreversibly decomposing is rife ...

As AI songs get harder to tell apart from human-made music, an older technology offers a revealing preview of the fight over ...

An informational report covering Mind Lab Pro's 11-ingredient nootropic formula, referenced clinical study results, dosage ...

Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026Received favorable FDA feedback on De Novo ...